Skip to the answer

Alogliptin / Pioglitazone Uses, Dosage, Side Effects and Interactions

Brand name
Oseni

Oseni was approved by the FDA in January 2013 as a tablet. The FDA rates no generic as a substitute for it.

Alogliptin / Pioglitazone is a two-in-one tablet taken by mouth, sold as Oseni and as generic alogliptin and pioglitazone, that helps control blood sugar in adults with type 2 diabetes along with diet and exercise.

Dr. Brian Staiger, PharmD, BCPS
Last reviewed Jul 10, 2026 Content updated Nov 7, 2026 Where our facts come from

Quick links

Ask Anything About Alogliptin / PioglitazoneType a question in your own words. Answered from its FDA label in seconds.

Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.

Alogliptin / Pioglitazone in Short

The Pharmacist’s Take

Dr. Brian Staiger, PharmD, BCPS
Clinical pharmacist Written

Alogliptin/pioglitazone (Oseni) is a tablet for type 2 diabetes that pairs alogliptin, which boosts gut hormones that trigger insulin release after meals, with pioglitazone, which helps your body use its own insulin; it is usually an add-on rather than a first choice, on the market since about 2012 with FDA-approved generics listed. It is generally well tolerated; cold-like symptoms, back pain and mild ankle swelling are what people notice most. The boxed warning is heart failure, so report fast weight gain, shortness of breath or swelling in your legs right away, especially after starting or raising the dose. Expect a liver test before you start, plus regular eye exams.

Key Takeaways From the HelloPharmacist Team

  • Take it once a day, with or without food, swallow it whole, and never double the next dose after a missed one.
  • Expect the full blood sugar effect to build slowly over several weeks, because the pioglitazone half takes time to work.
  • Stop the medicine and get medical care for severe stomach pain spreading to your back, a possible sign of an inflamed pancreas.
  • Ask whether your plan covers an FDA-approved generic, since generics of this combination are listed alongside brand Oseni.

How we write and review this content: our editorial policy

FDA Boxed WarningThe FDA’s strongest safety alert. Read what it says about Alogliptin / Pioglitazone.

This medicine can cause or worsen congestive heart failure. Pioglitazone, one of its two ingredients, makes some people hold extra fluid.

Watch for fast weight gain, shortness of breath and swelling, especially after starting or raising the dose. Call your doctor right away if you notice these. It is not recommended if you have symptomatic heart failure, and it must not be started if you have NYHA Class III or IV heart failure.

Read the full warning on DailyMed →

Alogliptin / Pioglitazone by the Numbers

Strengths
4
in one form
Makers and packagers
2
Earliest FDA record
2012
Rank by Medicaid prescriptions
#1,364 of 1,682 drugs
More prescriptions than 18% of the 1,682 drugs we measure
800 prescriptions, Q1–Q4 2025

Patient Information Guide for Alogliptin / Pioglitazone

What It’s Used For

This combination tablet is used for type 2 diabetes in adults.

  • Alogliptin and Pioglitazone tablets and Oseni (oral tablets) are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
  • They are not recommended for type 1 diabetes.

How It Works

Alogliptin is a DPP-4 inhibitor. It blocks an enzyme that breaks down incretin hormones, so those hormones last longer, help release insulin when blood sugar is high and lower the sugar made by the liver.

Pioglitazone is a thiazolidinedione. It lowers insulin resistance in your muscle, fat and liver so your own insulin works better. It does not make the pancreas release more insulin.

Drug Class

Drug Class

  • Dipeptidyl Peptidase 4 Inhibitor from alogliptin
  • Peroxisome Proliferator-activated Receptor alpha Agonist from pioglitazone
  • Peroxisome Proliferator-activated Receptor gamma Agonist from pioglitazone
  • Thiazolidinedione from pioglitazone
Detailed classifications and sources

The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class. Alogliptin / Pioglitazone has two active ingredients, so each class says which one it comes from.

Drug Class

Established Pharmacologic Class (EPC)
  • Dipeptidyl Peptidase 4 Inhibitor from alogliptin
  • Peroxisome Proliferator-activated Receptor alpha Agonist from pioglitazone
  • Peroxisome Proliferator-activated Receptor gamma Agonist from pioglitazone
  • Thiazolidinedione from pioglitazone

The main drug class the FDA gives it. It is the class named on the drug’s label.

How It Works

Mechanism of action (MoA)
  • Dipeptidyl Peptidase 4 Inhibitors from alogliptin
  • Peroxisome Proliferator-activated Receptor alpha Agonists from pioglitazone
  • Peroxisome Proliferator-activated Receptor gamma Agonists from pioglitazone

What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.

What It Does in the Body

Physiologic effect (PE)

None listed for Alogliptin / Pioglitazone in the FDA’s index.

From our Patient Information GuideAlogliptin is a DPP-4 inhibitor. It blocks an enzyme that breaks down incretin hormones, so those hormones last longer, help release insulin when blood sugar is high and lower the sugar made by the liver. Pioglitazone is a thiazolidinedione. Read How Alogliptin / Pioglitazone Works

A change it makes in how the body works.

Chemical Family

Chemical structure (CS)
  • Thiazolidinediones from pioglitazone

The chemical family it belongs to, by its structure.

Drug Family

WHO ATC classification
  • Combinations of oral blood glucose lowering drugs

How the World Health Organization groups it: by the part of the body it acts on and what it treats.

The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.

Dosage

Take one tablet by mouth once a day, with or without food. Do not split it.

Your prescriber chooses the strength based on your current diabetes medicines, kidney function and heart condition.

  • If you miss a dose, do not take a double dose next time.
  • Liver tests are done before you start, and kidney function is checked before and during treatment.
  • The dose is limited if you take gemfibrozil or similar medicines.

Typical Doses

Your prescriber chooses your dose, so take it exactly as prescribed.

Not treated with either alogliptin or pioglitazone, starting dosage

For adults not taking alogliptin or pioglitazone · Starting dose
Starting dose 25 mg of alogliptin/15 mg or 25 mg/30 mg once a day Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a day

Currently treated with alogliptin, starting dosage

For adults already taking alogliptin · Starting dose
Starting dose 25 mg of alogliptin/15 mg or 25 mg/30 mg once a day Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a day

Currently treated with pioglitazone, starting dosage

For adults already taking pioglitazone · Starting dose
Starting dose 25 mg of alogliptin/15 mg, 25 mg/30 mg, or 25 mg/45 mg of pioglitazone once a day Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a day

Currently treated with alogliptin and pioglitazone, starting dosage

For adults already taking alogliptin and pioglitazone · Starting dose
Highest dose 25 mg of alogliptin and 45 mg of pioglitazone once a day
  • Select a dosage that is as close as possible to the current dosage of alogliptin and pioglitazone

NYHA class I or II congestive heart failure, starting dosage

For adults · Starting dose
Starting dose 25 mg of alogliptin and 15 mg of pioglitazone

Good to know

Monitor for fluid retention; consider stopping or lowering pioglitazone if heart failure develops

Type 2 diabetes (blood sugar control)

For adults also taking gemfibrozil or similar medicines
Highest dose 25 mg of alogliptin and 15 mg of pioglitazone once a day
  • Maximum 25 mg of alogliptin and 15 mg of pioglitazone once daily

Other Doses

Adults with moderate kidney problems Usual dose 12.5 mg of alogliptin and 30 mg of pioglitazone once a day

Good to know

Not recommended with severe renal impairment (CrCl ≥15 to <30 mL/min) or ESRD

CrCl means creatinine clearance, a measure of how well the kidneys work.

ESRD means end-stage renal disease (kidney failure).

See the Full Dosing Instructions on DailyMed →

Side Effects

The most common side effects in studies were:

Common side effects

  • Stuffy or runny nose and sore throat (nasopharyngitis)
  • Back pain
  • Upper respiratory tract infection (cold-like symptoms)
  • Swelling (edema), which can be dose-related
  • Low blood sugar, especially with insulin or sulfonylurea medicines

When to get medical help

  • Rapid weight gain, shortness of breath or swelling in your legs or feet, which can be signs of heart failure. Report these right away.
  • Severe stomach pain that may spread to your back, with or without vomiting, which can be a sign of pancreatitis (inflamed pancreas). Stop the medicine and call your doctor.
  • Swelling of the face, lips or throat, trouble breathing, or a severe skin reaction. These can be signs of a serious allergic reaction.
  • Tiredness, loss of appetite, pain in the upper right belly, dark urine or yellow skin or eyes, which can signal liver problems.
  • Blurred or changed vision, which can be a sign of macular edema (swelling in the back of the eye).
  • Severe, disabling joint pain.
  • Blisters or raw patches on the skin, which can be a sign of bullous pemphigoid.
  • Bone fractures, which were more common in women taking pioglitazone.

Warnings and Precautions

  • Heart failure (boxed warning): pioglitazone can cause or worsen it. Watch for fast weight gain, swelling and shortness of breath.
  • Pancreatitis: stop the medicine if it is suspected.
  • Serious allergic reactions: including anaphylaxis, angioedema and Stevens-Johnson syndrome.
  • Liver problems: sometimes fatal liver failure has been reported.
  • Fractures: more common in women taking pioglitazone.
  • Bladder cancer: pioglitazone may raise the risk of bladder tumors, though studies disagree.
  • Low blood sugar: more likely with insulin or sulfonylureas.
  • Eye swelling, severe joint pain and blistering skin disease have also been reported.

Interactions

A few medicines can change how this tablet works or raise the risk of side effects.

  • Gemfibrozil and other strong CYP2C8 inhibitors: raise pioglitazone levels, so the maximum dose is limited.
  • Rifampin and other CYP2C8 inducers: may lower pioglitazone levels, so treatment may need adjusting.
  • Topiramate: may lower pioglitazone levels, so blood sugar should be monitored.
  • Insulin and sulfonylureas: raise the risk of low blood sugar, so their doses may need to be lowered.

Interactions Listed in the FDA-Approved Label

From the Alogliptin / Pioglitazone prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.

  • Insulin secretagogues (e.g., sulfonylurea) and insulin
    What happensKnown to cause hypoglycemia; combined use may require lower dosages of the secretagogue or insulin.
    What to doLower dosages of the insulin secretagogue or insulin may be needed to reduce the risk of hypoglycemia.
  • Strong CYP2C8 inhibitors For example: gemfibrozil
    What happensSignificantly increase pioglitazone exposure (AUC) and half-life.
    What to doMaximum 25 mg of alogliptin and 15 mg of pioglitazone once daily.
  • CYP2C8 inducers For example: rifampin
    What happensMay significantly decrease pioglitazone exposure (AUC).
    What to doIf an inducer is started or stopped, changes in diabetes treatment may be needed, without exceeding 25 mg of alogliptin and 45 mg of pioglitazone.
  • What happensDecreases exposure of pioglitazone and its active metabolites; clinical relevance unknown.
    What to doMonitor patients for adequate glycemic control.
Read the label’s full interactions text

7 DRUG INTERACTIONS Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit the pioglitazone dose to 15 mg daily. CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. Topiramate may decrease pioglitazone concentrations. 7.1 Insulin Secretagogues and Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. Coadministration of alogliptin and pioglitazone tablets with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower dosages of the insulin secretagogue and insulin to reduce the risk of hypoglycemia. 7.2 Strong CYP2C8 Inhibitors An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the concentration-time curve [AUC]) and half-life of pioglitazone. Therefore, the maximum recommended dosage of alogliptin and pioglitazone tablets is 25 mg of alogliptin and 15 mg of pioglitazone once daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors. 7.3 CYP2C8 Inducers An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with alogliptin and pioglitazone tablets, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of alogliptin and pioglitazone tablets (25 mg of alogliptin and 45 mg of pioglitazone). 7.4 Topiramate A decrease in the exposure of pioglitazone and its active metabolites were noted with concomitant administration of pioglitazone and topiramate.

Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →

Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.

Before You Start

  • Do not use it if you have established NYHA Class III or IV heart failure, or a past serious allergy to alogliptin, pioglitazone or the tablet ingredients.
  • Tell your prescriber about heart failure, swelling, kidney disease or liver disease.
  • Tell your prescriber about active or past bladder cancer.
  • Kidney function is checked first. Moderate kidney impairment needs a lower dose. It is not recommended for severe kidney disease or dialysis.
  • Pregnancy: human data are limited, and poorly controlled diabetes carries its own risks. Premenopausal women should know pioglitazone may cause ovulation and an unintended pregnancy.
  • Breastfeeding: no human milk data are available, so discuss it with your prescriber.
  • Children: not recommended.
  • Older adults: no overall differences in safety or effectiveness were seen.

Overdose

In an overdose, doctors provide supportive care and monitoring, and may remove unabsorbed drug from the stomach and intestines. Dialysis is unlikely to help. Call Poison Help at 1-800-222-1222 right away.

How Your Body Processes It

The combination tablet delivers both drugs similarly to taking them separately, and food does not significantly change absorption. Alogliptin is mostly cleared unchanged by the kidneys. Pioglitazone is broken down extensively in the liver, mainly by the CYP2C8 enzyme, into active metabolites. Steady levels of pioglitazone are reached within about seven days of daily use.

Storage

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) . Protect from moisture and humidity.

Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Alogliptin / Pioglitazone: Pharmacist Answers to Common Questions

Quick, plain-English answers to the questions patients ask most about Alogliptin / Pioglitazone — the kind of thing our pharmacy team would talk through with you at the counter.

What is alogliptin / pioglitazone used for?

It helps control blood sugar in adults with type 2 diabetes, along with healthy eating and exercise. It combines two medicines that work in different ways. It is not for type 1 diabetes.

How do I take alogliptin / pioglitazone?

Swallow one tablet by mouth once a day. You can take it with or without food. Don't split the tablet. Follow the directions from your prescriber and the label on your bottle.

What happens if I miss a dose of alogliptin / pioglitazone?

Don't take a double dose to catch up. Just take your next dose at the usual time. If you often forget, ask me for tips on building a routine.

What side effects should I expect, and which ones mean I should call?

Common ones include cold-like symptoms, back pain and some swelling. Call your doctor promptly for fast weight gain, shortness of breath, swelling in your legs, severe stomach pain, yellow skin or eyes, vision changes, severe joint pain, skin blisters or signs of an allergic reaction.

Is alogliptin / pioglitazone safe if I have heart failure?

It carries a boxed warning because pioglitazone can cause or worsen heart failure. It must not be started if you have NYHA Class III or IV heart failure, and it isn't recommended with symptomatic heart failure. Tell your doctor about any heart problems before you start.

Does alogliptin / pioglitazone interact with other medicines?

Yes. Gemfibrozil raises pioglitazone levels, so your dose is capped. Rifampin and topiramate may lower pioglitazone levels. If you also take insulin or a sulfonylurea, your doctor may lower those doses to avoid low blood sugar.

Is alogliptin / pioglitazone available over the counter?

No. Alogliptin / pioglitazone is a prescription medicine: every alogliptin / pioglitazone product listed with the FDA is prescription only, so it is not sold over the counter. Your prescriber decides whether it is appropriate for you, and your pharmacist dispenses it.

When was alogliptin / pioglitazone first available?

The earliest FDA record we hold for alogliptin / pioglitazone is from 2012: its first approval in Drugs@FDA or its earliest product listing in the NDC Directory, whichever is older. Many older medicines were in use before their first formal FDA approval, so this is the earliest date on record, not necessarily when alogliptin / pioglitazone was first used.

Who makes alogliptin / pioglitazone?

2 companies currently list alogliptin / pioglitazone products in the FDA's NDC Directory, including Padagis Israel Pharmaceuticals Ltd, Takeda Pharmaceuticals America, Inc.. That count includes repackagers and distributors as well as manufacturers (companies that sell only the raw ingredient are not counted), so fewer companies actually make it; the label on your bottle names the one that supplied yours.

What is the brand name of alogliptin / pioglitazone?

Alogliptin / pioglitazone is the generic name. Its brand name is Oseni. Generic versions are listed under the name alogliptin / pioglitazone.

What is the generic name of Oseni?

The generic name of Oseni is alogliptin / pioglitazone. A generic name is the name of the active ingredients, the same whichever company makes the medicine; a brand name belongs to one company. Your prescription label may show either name.

What drug class is alogliptin / pioglitazone?

Alogliptin / pioglitazone belongs to the drug class Dipeptidyl Peptidase 4 Inhibitor, Peroxisome Proliferator-activated Receptor alpha Agonist, Peroxisome Proliferator-activated Receptor gamma Agonist and Thiazolidinedione, its established pharmacologic class on the FDA label.

Is there a generic version of alogliptin / pioglitazone?

Yes. FDA-approved generic versions of alogliptin / pioglitazone are listed in the FDA's National Drug Code Directory. A listing does not prove that every pharmacy stocks one, so your pharmacy can tell you which version it carries.

What strengths does alogliptin / pioglitazone come in?

Alogliptin / pioglitazone is listed in the FDA's National Drug Code Directory in these forms and strengths. Tablet (by mouth): 12.5 mg/30 mg, 25 mg/15 mg, 25 mg/30 mg and 25 mg/45 mg. A listing does not mean every pharmacy stocks every strength.

How much does alogliptin / pioglitazone cost?

What you pay depends on your insurance, your pharmacy and the strength you take. As a benchmark, pharmacies paid a national average of $4.73 per ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg generic tablet as of November 18, 2026 (CMS's NADAC survey). That is the pharmacy's own cost for the medicine, not the price at the counter. The pharmacy prices section of this page lists every strength priced.

Where can I read the alogliptin / pioglitazone prescribing information (package insert)?

The full FDA-approved prescribing information for alogliptin / pioglitazone, also called the package insert or drug label, is published on DailyMed, the National Library of Medicine's library of FDA labels. Each company's version has its own label; this page is built from Padagis Israel Pharmaceuticals Ltd's, revised Jul 28, 2025, and links to it on DailyMed.

Can you crush alogliptin / pioglitazone?

Some forms of alogliptin / pioglitazone are on our Do Not Crush list of tablets and capsules that should not be crushed or chewed: Alogliptin benzoate-pioglitazone hydrochloride (tablet); Oseni (tablet). They are listed for a reason such as irritation, a bad taste or a special formulation. A form that is not on the list may still come with its own instructions, so check the label and ask your pharmacist before you crush, split or open any medicine. Each listed form’s reason and instructions are on our Do Not Crush list.

Is alogliptin / pioglitazone gluten free?

No alogliptin / pioglitazone label we read lists an ingredient made from wheat, barley or rye, the grains that carry gluten, and none names a starch, dextrin or maltodextrin without saying where it comes from. We read the FDA labels of 8 alogliptin / pioglitazone products from 2 companies. A label lists ingredients; it is not a gluten test, so we cannot promise that any product has no gluten. If you have celiac disease, ask the company for a written gluten statement. Our Inactive Ingredient Checker shows each company's alogliptin / pioglitazone by strength and NDC, and whether its label lists a gluten source, lactose, dyes or any other inactive ingredient. See alogliptin / pioglitazone inactive ingredients by company

Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI

Ask Anything About Alogliptin / Pioglitazone

Skip the scrolling. Ask in your own words and get an answer from Alogliptin / Pioglitazone’s FDA label and our pharmacists’ own work.

Try:

Name another drug or a supplement in your question and we check both.

AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
  • Sources: Alogliptin / Pioglitazone’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
  • Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
  • Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
  • Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.

More About Alogliptin / Pioglitazone on HelloPharmacist

Still have a question? A licensed pharmacist answers for free, as soon as they can.
Detailed Data & References for Alogliptin / Pioglitazone Forms and strengths, pricing, billing codes, manufacturers, safety reports and sourcing: the data behind the page. Most people can stop here. Each section below opens on a tap.

Alogliptin / Pioglitazone Forms and Strengths (How It Comes)

Alogliptin / Pioglitazone comes in 1 dose form, the tablet. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.

Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Alogliptin / Pioglitazone inactive ingredients by manufacturer.

Tablet

By mouth
Brands Oseni (2013)
How this form is used
What it may be used for
  • Alogliptin and Pioglitazone tablets are used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
  • Oseni is used with diet and exercise to improve blood sugar control in adults with type 2 diabetes.
Important instructions
  • Oseni is taken by mouth once daily, with or without food.
  • Oseni tablets should not be split.
  • Alogliptin and Pioglitazone tablets are taken by mouth once daily, with or without food.
  • With Alogliptin and Pioglitazone tablets, do not double the next dose if you miss one.
Available strengths 4 strengths
8 FDA-listed product records ⓘ

Alogliptin / Pioglitazone on the U.S. Market: Products, Makers and Brands

How Alogliptin / Pioglitazone appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.

2 companies list 8 Alogliptin / Pioglitazone product records with the FDA, mostly as tablet; the earliest marketing or approval year on record is 2012. The one brand name in the directory today is Oseni; the rest are generics.

1
Dose forms ⓘ
2
Labelers (makers, repackagers, distributors)
1
Brand names ⓘ
8
FDA-listed product records ⓘ
2012
Earliest FDA record ⓘ

Also listed with the FDA, not a patient dose form: Unfinished tablet, film coated (10) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.

Padagis Israel Pharmaceuticals Ltd50%
Takeda Pharmaceuticals America, Inc.50%

Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.

How Widely Alogliptin / Pioglitazone Is Used (Medicaid Data)

How many Alogliptin / Pioglitazone prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.

800
Medicaid prescriptions filled (Q1–Q4 2025)
$265,023 paid by Medicaid, before rebates

How commonly is Alogliptin / Pioglitazone prescribed? Of the 1,682 medications we measure, Alogliptin / Pioglitazone ranks #1,364 by Medicaid prescriptions — more than 19% of them.

Where Alogliptin / Pioglitazone ranks among the drugs we measure · Q1–Q4 2025 · neighbors ±5

Utilization by Alogliptin / Pioglitazone product

Pick a strength and form to see its own numbers. Brand and generic versions are counted together.

The 25 mg / 30 mg oral tablet is the most-dispensed Alogliptin / Pioglitazone product — about 47% of these Medicaid prescriptions.

alogliptin 25 MG / pioglitazone 30 MG Oral Tablet Most dispensed

373 Medicaid prescriptions (Q1–Q4 2025) 47% of Alogliptin / Pioglitazone prescriptions shown $112,207 paid by Medicaid, before rebates ≈ $301 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 1368431

alogliptin 25 MG / pioglitazone 15 MG Oral Tablet

207 Medicaid prescriptions (Q1–Q4 2025) 26% of Alogliptin / Pioglitazone prescriptions shown $71,750 paid by Medicaid, before rebates ≈ $347 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 1368424

alogliptin 25 MG / pioglitazone 45 MG Oral Tablet

207 Medicaid prescriptions (Q1–Q4 2025) 26% of Alogliptin / Pioglitazone prescriptions shown $77,208 paid by Medicaid, before rebates ≈ $373 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 1368438

alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet

13 Medicaid prescriptions (Q1–Q4 2025) 2% of Alogliptin / Pioglitazone prescriptions shown $3,858 paid by Medicaid, before rebates ≈ $297 per prescription, before rebates

1 of 6 listed NDCs had Medicaid claims. RxNorm 1368410

Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.

Source: Medicaid State Drug Utilization Data (CMS), all states. 4 of the 24 listed Alogliptin / Pioglitazone NDCs had Medicaid claims.

Compare Alogliptin / Pioglitazone Products

A representative set of FDA-listed product records for Alogliptin / Pioglitazone — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)

Strength Route Manufacturer / Labeler Category ⓘ Details
💊Tablet
ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg Oral Padagis Israel Pharmaceuticals Ltd NDA AUTHORIZED GENERIC View NDC →
ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg Oral Padagis Israel Pharmaceuticals Ltd NDA AUTHORIZED GENERIC View NDC →
ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg Oral Padagis Israel Pharmaceuticals Ltd NDA AUTHORIZED GENERIC View NDC →
ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg Oral Padagis Israel Pharmaceuticals Ltd NDA AUTHORIZED GENERIC View NDC →
ALOGLIPTIN BENZOATE 12.5 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg Oral Takeda Pharmaceuticals America, Inc. NDA View NDC →
ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg Oral Takeda Pharmaceuticals America, Inc. NDA View NDC →
ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 30 mg Oral Takeda Pharmaceuticals America, Inc. NDA View NDC →
ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 45 mg Oral Takeda Pharmaceuticals America, Inc. NDA View NDC →

Showing 8 of 8 products — FDA National Drug Code Directory. See every product, package size and price: browse all 8 Alogliptin / Pioglitazone NDCs →

Alogliptin / Pioglitazone Recall History

A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.

The FDA’s enforcement reports list no Alogliptin / Pioglitazone recalls since July 2021.

✅No Alogliptin / Pioglitazone recalls on record since July 2021

Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.

Alogliptin / Pioglitazone in RxNorm: From Ingredient to Every Form and Strength

RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one exact combination of ingredients (MIN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. A different combination is a different concept with its own page.

Dose forms
1
Strengths
6
Forms in current FDA listings
1 of 1
In current FDA listings No current FDA listing
Multiple ingredients (MIN) Alogliptin / Pioglitazone RxCUI 1368402
  1. Dose form (SCDF) Oral Tablet RxCUI 1368401
    In current FDA listings
    Its 6 strengths (SCD)

RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.

What Alogliptin / Pioglitazone Costs Pharmacies (NADAC Benchmark)

What pharmacies pay to buy Alogliptin / Pioglitazone: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.

How the Pharmacy Price Has Changed

Pick a strength to see how its price has changed since Jul 2024.

Strength

For the generic ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg tablet, pharmacies paid an average of $4.73 per tablet as of Nov 18, 2026, down 14% from $5.52 a year earlier.

What pharmacies pay now
$4.73
per tablet, as of Nov 18, 2026
Last 4 weeks
No change
from $4.73 on Oct 21, 2026
Last 12 months
Down 14%
from $5.52 on Nov 19, 2025
Lowest and highest since Jul 2024
$4.73 to $5.52
per tablet

Each step is one weekly survey. Arrow keys on the chart move week by week.
See the numbers, month by month
Generic ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg tablet: the average pharmacy price per tablet, the last survey of each month
MonthPharmacy price
Nov 2026$4.73
Oct 2026$4.73
Sep 2026$4.73
Dec 2025$5.52
Nov 2025$5.52
Oct 2025$5.52
Sep 2025$5.52
Aug 2025$5.52
Jul 2025$5.52
Jun 2025$5.52
May 2025$5.52
Apr 2025$5.52
Mar 2025$5.52
Feb 2025$5.52
Jan 2025$5.52
Dec 2024$5.52
Nov 2024$5.52
Oct 2024$5.52
Sep 2024$5.42
Aug 2024$5.42
Jul 2024$5.31
FormStrengthVersion What pharmacies pay
Tablet · Oral ALOGLIPTIN BENZOATE 25 mg/1; PIOGLITAZONE HYDROCHLORIDE 15 mg Generic $4.73 per tablet NDC details & price history
Why it helps: it shows whether the drug itself is cheap or costly, and whether a cash price you are quoted is in a reasonable range. What you pay also depends on your insurance and pharmacy.

Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.

Alogliptin / Pioglitazone Brand Names

Alogliptin / Pioglitazone has one brand name on record: Oseni. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.

Oseni 2013

Who Makes Alogliptin / Pioglitazone: Manufacturers and Labelers

2 companies list Alogliptin / Pioglitazone products with the FDA. By number of product records, the largest are Padagis Israel Pharmaceuticals Ltd, Takeda Pharmaceuticals America, Inc.. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.

Padagis Israel Pharmaceuticals Ltd 4 Takeda Pharmaceuticals America, Inc. 4

Sources for This Alogliptin / Pioglitazone Page

Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.

📄
FDA-filed drug labels (SPL) Uses, dosing, warnings & side effects from SPL records retrieved through openFDA; the linked representative set can be verified on DailyMed. Prescribing information dated Jul 28, 2025, the label version this page reads. A label changes when the FDA approves new uses, doses or warnings, so this is not the day the page itself last changed. Read the full label on DailyMed
🏭
Forms, brands & labelersAggregated from ingredient-matched FDA National Drug Code Directory product records for Alogliptin / Pioglitazone.
📈
Real-world reportsThe FDA Adverse Event Reporting System (FAERS), served through openFDA.
🚨
Recalls & shortagesopenFDA drug-enforcement reports and the FDA drug-shortage database.

Where this information comes from

The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 2 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source.

Clinical labels in scope
2
Finished products in the current FDA directory
8
Companies listing them (makers, repackagers, distributors)
2
FDA labeler codes behind them ⓘ
2
Linked representative label ⓘ
Padagis Israel Pharmaceuticals Ltd
Linked label effective
Jul 28, 2025
Composite sections available
24
Linked SPL Set ID
642b1e90-701e-42f2-bac6-a4918738e2c9
Linked SPL Document ID
11c471e0-6c64-4f13-b6ed-d2c80bc89f20
Open the linked representative label on DailyMed ↗

How this page is built

HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Padagis Israel Pharmaceuticals Ltd is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →